Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Diamyd commences NP2 Enkephalin Phase II trial to reduce cancer pain

Diamyd has dosed the first subject in a Phase II clinical trial in the United States evaluating the ability of the candidate drug NP2 Enkephalin to reduce cancer pain.

17 Jan 2011

Inflammation “master switch” found: Study

According to the latest medical discovery a protein that acts as a “master switch” has been found to determine whether certain white blood cells will boost or dampen inflammation. This may open new avenues in rheumatoid arthritis research. Rheumatoid arthritis or RA is an inflammatory disease that causes severe progressive crippling of the joints.

17 Jan 2011

Health Canada requests Osiris for additional information in support of Prochymal approval

Osiris Therapeutics, Inc. today announced that Health Canada has requested additional information in support of the Company's application for approval of Prochymal, a stem cell therapy, for the treatment of graft vs. host disease (GvHD).

14 Jan 2011

CINJ clinical trial explores anti-malaria drug against melanoma

Building upon recent laboratory discoveries on resistance by cancer cells to therapies that attempt to starve cancer, scientists at The Cancer Institute of New Jersey (CINJ) are conducting a clinical trial that further explores how to prevent that action.

14 Jan 2011

Therapeutic workshops selected for presentation at the Thirteenth Annual BIO CEO & Investor Conference

The Biotechnology Industry Organization (BIO) today announced the selection of therapeutic workshops to be presented at the Thirteenth Annual BIO CEO & Investor Conference, taking place February 14-15.

13 Jan 2011

GSK, ChemoCentryx initiate '786 Phase III clinical trial for Crohn's disease

GlaxoSmithKline and ChemoCentryx, announced today that the first patient with Crohn's disease has initiated treatment in the initial pivotal induction study comparing Traficet-EN, now designated GSK1605786 ('786), to placebo.

12 Jan 2011

PLoS Neglected Tropical Diseases features Inovio’s Chikungunya DNA vaccine

Inovio Pharmaceuticals, Inc., a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the publication of a scientific paper highlighting positive results from Inovio's multi-antigen Chikungunya virus (CHIKV) DNA vaccine in PLoS Neglected Tropical Diseases.

12 Jan 2011

Tri-Valley Medical Group physicians discuss issues impacting roll-out of health care reform

Local physicians from Tri-Valley Medical Group recently spent a week in Washington D.C. to discuss the fundamental issues impacting the roll-out of health care reform - and came away with a new appreciation of its challenges.

11 Jan 2011

New study on being medically prepared for natural disasters

Imagine having to evacuate your home quickly as 60 mph winds shatter your windows, water crawls under your front door and the electricity cuts leaving your house as dark as the inside of a coffee can. Would you be prepared? Now visualize being one of the 56 million Americans with a disability, such as wheelchair dependence, or one of the 133 million with a chronic disease, such as asthma.

11 Jan 2011

TransPharma reports positive results from ViaDerm-Calcitonin Phase 1 trial for musculoskeletal disorders

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today successful results of a Phase I clinical trial of its self-applied ViaDerm-Calcitonin product for the treatment of musculoskeletal disorders such as osteoarthritis and musculoskeletal pain.

11 Jan 2011

U.S. District Court grants injunction for Sensipar patents

A U.S. District Court in Delaware today granted an injunction preventing Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals Industries Ltd., and Barr Laboratories, Inc. from commercializing generic versions of Amgen's Sensipar® (cinacalcet) until expiration of the drug's U.S. patents.

10 Jan 2011

Entelos receives U.S. Patent for Predictive Toxicology for Biological Systems

Entelos, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 7,853,406 entitled "Predictive Toxicology for Biological Systems" to the Company.

9 Jan 2011

Sucampo, Takeda initiate dosing in third lubiprostone phase 3 trial for opioid-induced bowel dysfunction

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals North America, Inc. today announced the dosing of the first patient in the third phase 3 clinical trial of lubiprostone for the treatment of opioid-induced bowel dysfunction (OBD) in subjects with chronic, non-cancer pain, excluding those taking methadone. The primary endpoint is an overall responder rate based on the change from baseline in the reported frequency of spontaneous bowel movements (SBMs).

7 Jan 2011

Amgen, Xencor collaborate to develop XmAb5871 for autoimmune disease

Amgen and Xencor, announced today that they will collaborate to develop XmAb®5871, an Fc- engineered monoclonal antibody dually targeting CD19 and CD32b. XmAb5871 is currently in late-stage preclinical development for the treatment of autoimmune diseases.

7 Jan 2011

Ligand, Chiva Pharmaceuticals enter strategic relationship to develop multiple Ligand assets, technology

Ligand Pharmaceuticals Incorporated announced today that it has entered into a strategic relationship with Chiva Pharmaceuticals, to develop multiple Ligand assets and technology in China and potentially worldwide.

7 Jan 2011

Positive topline results from RDEA594 Phase 2b study in patients with gout, allopurinol

Ardea Biosciences, Inc. announced positive, preliminary, top-line results from its Phase 2b study of RDEA594 in combination with the current standard of care for the treatment of gout, allopurinol.

7 Jan 2011

Isis Pharmaceuticals announces addition of two new drugs to development pipeline

Isis Pharmaceuticals, announced today that it has added two new drugs to its development pipeline, ISIS-FGFR4Rx and ISIS-STAT3Rx.

7 Jan 2011

Medical experts issue warning about common practice of tablet splitting

Medical experts have issued a warning about the common practice of tablet splitting, after a study found that nearly a third of the split fragments deviated from recommended dosages by 15 per cent or more.

6 Jan 2011

InHealth awards grant to assess effects of hip replacement therapy on aging populations

The Institute for Health Technology Studies has awarded a grant of $240,000 to an international consortium of researchers, for a study that will assess the effects of hip replacement therapy on the employment and retirement decisions of older adults. Led by researchers at the Universit- Bocconi (Milan), the consortium also includes investigators at the University of York (York, UK), and the Johns Hopkins University School of Public Health (Baltimore).

6 Jan 2011

FDA awards supplemental approval to support efficacy of ACTEMRA in treating RA

Genentech, Inc., a member of the Roche Group, today announced that the United States Food and Drug Administration has extended the ACTEMRA (tocilizumab, RoACTEMRA in the European Union) label to include inhibition and slowing of structural joint damage, improvement of physical function, and achievement of major clinical response in adult patients with moderately to severely active rheumatoid arthritis, when given in combination with methotrexate.

6 Jan 2011

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Diamyd commences NP2 Enkephalin Phase II trial to reduce cancer pain

Inflammation “master switch” found: Study

Health Canada requests Osiris for additional information in support of Prochymal approval

CINJ clinical trial explores anti-malaria drug against melanoma

Therapeutic workshops selected for presentation at the Thirteenth Annual BIO CEO & Investor Conference

GSK, ChemoCentryx initiate '786 Phase III clinical trial for Crohn's disease

PLoS Neglected Tropical Diseases features Inovio’s Chikungunya DNA vaccine

Tri-Valley Medical Group physicians discuss issues impacting roll-out of health care reform

New study on being medically prepared for natural disasters

TransPharma reports positive results from ViaDerm-Calcitonin Phase 1 trial for musculoskeletal disorders

U.S. District Court grants injunction for Sensipar patents

Entelos receives U.S. Patent for Predictive Toxicology for Biological Systems

Sucampo, Takeda initiate dosing in third lubiprostone phase 3 trial for opioid-induced bowel dysfunction

Amgen, Xencor collaborate to develop XmAb5871 for autoimmune disease

Ligand, Chiva Pharmaceuticals enter strategic relationship to develop multiple Ligand assets, technology

Positive topline results from RDEA594 Phase 2b study in patients with gout, allopurinol

Isis Pharmaceuticals announces addition of two new drugs to development pipeline

Medical experts issue warning about common practice of tablet splitting

InHealth awards grant to assess effects of hip replacement therapy on aging populations

FDA awards supplemental approval to support efficacy of ACTEMRA in treating RA

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in